But the Australian missionary, who has become a naturalised PNG citizen because of the decades he spent doing missionary work in PNG, would not back down. At a meeting for the church clergy in East ...

It is going to look a little bizarre, but there is a great reason behind the change… Nike have changed their logo on third kits to celebrate women's football. They explained their switch for ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

Ultimately, Ucraft offers a very basic free AI logo generator - but it’s also very easy to use. On the free tier, you can download a 600px PNG file. For a high-resolution SVG, you’ll need to ...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients. In the final ...

A Reddit thread started Thursday titled, "What's wrong with the Facebook logo?" shows a blue lowercase "f" on a black background instead of a blue background with a white "f." Some users who have ...

Kisqali is a prescription drug used with other medications to treat certain kinds of breast cancer. Kisqali can cause side effects that range from mild to serious, such as fatigue, hair loss, and ...

While sparse data makes accurate measurement difficult, most would agree violence and lawlessness are increasing in many parts of PNG. The broader context for this violence includes: rural decay ...

This year’s PNG Update marks a decade since it was instituted in 2014 as a purpose-driven program to have economic-related updates around the country to be presented by researchers in all professions.

This type of tumor, referred in shorthand as HR+ and HER2-, accounts for roughly 70% of all breast cancer cases in the U.S. Kisqali specifically targets a protein called CDK4/6, as does Eli Lilly’s ...

Just a few weeks after Eli Lilly claimed a key FDA approval for its CDK4/6 inhibitor Verzenio in early-stage breast cancer, Novartis has responded with phase 3 data for Kisqali that will lead to ...